Eli Lilly has pulled the plug on a phase 2b obesity trial before enrolling a sin | Eli Lilly has pulled the plug on a phase ...

Merck & Co. is choosing to license one of Evaxion’s AI platform-based vaccine candidates, offering the Danish biotech up to ...

The FDA’s rejection of Telix Pharmaceuticals’ imaging agent has triggered layoffs at Heidelberg Pharma. | The FDA’s rejection ...

Sparrow Pharmaceuticals is looking to send its potential diabetes treatment soaring through clinical trials with the help of ...

UniQure has set its sights on submitting its Huntington’s disease gene therapy for approval next year after the asset was ...

Lantheus has inked a deal giving GE HealthCare the rights to carry its prostate cancer PET imaging agent in Japan, with the ...

While the average earnout potential per biopharma deal has declined over the last five years, the mean upfront value has been ...

Heartflow has secured a new FDA clearance for its artificial intelligence program to analyze the buildup of dangerous plaques ...

Harmony Biosciences’ $60 million bet on a once-failed Fragile X candidate has gone off the rails. | Harmony Biosciences’ $60 million bet on a once-failed Fragile X candidate has gone off the rails.

When it comes to Cyclerion Therapeutics' colorful backstory, the only consistency has been its inconsistency. | When it comes ...

Sanofi is bestowing $625 million on its investment arm Sanofi Ventures, seeking to take advantage of a biotech landscape that ...

Tuesday morning, Seres confirmed that one of these actions would involve reducing its workforce by 25%. Employees who are ...